Kintara Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Kintara Therapeutics, Inc.

Kintara Therapeutics, Inc. (ticker: KTRA) is a United States biopharmaceutical company listed on the NASDAQ market, and its headquarters are in San Diego, California, United States. The company’s modern identity was shaped by its 2020 merger with Adgero Biopharmaceuticals and the earlier evolution of DelMar Pharmaceuticals, after which the combined company adopted the Kintara name and began trading on Nasdaq Capital Market under the KTRA symbol. That corporate history matters because Kintara has been built as a development-stage oncology platform rather than as a commercial drug business. ([kintara.com](https://www.kintara.com/news-media/press-releases/detail/939/kintara-therapeutics-formerly-delmar-pharmaceuticals?utm_source=openai)) Kintara’s core focus has been the development of novel anti-cancer therapies for patients with high unmet medical need. Public company materials describe a strategy centered on scientifically grounded programs aimed at solid tumors, especially settings where patients are failing current standards of care or cannot tolerate them. Historically, its best-known assets have included VAL-083, a small-molecule anticancer compound evaluated in drug-resistant solid tumors such as glioblastoma, and REM-001 Therapy, a light-activated treatment comprising a laser light source, a light delivery device, and the REM-001 drug product, previously studied in cutaneous metastatic breast cancer. ([kintara.com](https://www.kintara.com/pipeline?utm_source=openai)) From a competitive standpoint, Kintara operates in a highly demanding oncology biotech niche where differentiation depends on clinical data, regulatory milestones, and capital access. It does not have the broad commercial infrastructure or diversified revenue base of large pharmaceutical companies; instead, investor value is tied to pipeline execution, trial outcomes, and financing flexibility. That makes KTRA a classic small-cap biotech profile: potentially high upside if a program advances successfully, but equally exposed to clinical, regulatory, and funding risk. ([kintara.com](https://www.kintara.com/pipeline?utm_source=openai)) Geographically, the business is primarily U.S.-based, with operations anchored in San Diego, California. The company’s SEC filings and corporate materials confirm that headquarters location, and its NASDAQ listing places it squarely within the U.S. public small-cap biotechnology universe. For French-speaking investors, that means KTRA should be viewed as an American development-stage oncology name rather than a mature, revenue-driven healthcare company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1498382/000095017024113321/ktra-20240630.htm?utm_source=openai)) Recent company updates indicate that Kintara has continued to provide financial and corporate disclosures through SEC filings and press releases, while remaining focused on solid-tumor cancer therapies. The most relevant recent public narrative is not one of commercial expansion, but of pipeline maintenance, corporate transformation, and ongoing clinical-development optionality. In practical terms, KTRA is best analyzed as a speculative biotech equity whose market value is driven by trial progress, strategic transactions, and the ability to fund development over time. ([kintara.com](https://www.kintara.com/news-media/press-releases/detail/1049/kintara-therapeutics-announces-fiscal-2024-financial?utm_source=openai))